Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfachlorpyridazine is a synthetic small molecule belonging to the sulfonamide class of antibiotics. It acts as a broad-spectrum antibacterial agent, effective against both gram-positive and gram-negative bacteria, including *Escherichia coli*. Its primary use is in veterinary medicine for the treatment of infections such as diarrhea (colibacillosis) in calves and swine caused or complicated by *E. coli*[1][4][5]. The mechanism of action involves competitive inhibition of the bacterial enzyme dihydropteroate synthase, thereby blocking dihydrofolic acid synthesis required for folic acid production and ultimately inhibiting bacterial growth[6][8]. Sulfachlorpyridazine is approved for veterinary use and may also be used to study metabolic pathways in microbiology research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfachlorpyridazine.